Compare Mesoblast Limited (MESO) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Millicom International Cellular S.A. Common Stock — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Millicom International Cellular S.A. Common Stock trades at $80.5 (market cap $13.34B). The key difference: Millicom International Cellular S.A. Common Stock is far larger — about 7.3× Mesoblast Limited's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| MESO | TIGO | |
|---|---|---|
Market Cap | $1.83B | $13.34B |
Volume | 259,445 | 1,586,684 |
Sector | Health | Media |
52-Week High | $20.96 | $104.31 |
52-Week Low | $13.19 | $45.81 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $24.38B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
